DBV Technologies: MPM BioImpact reports 4.8% stake

Available on EDGAR 11/13/2026 - 12:26 PM EST Accepted by SEC EDGAR 11/13/2026 - 12:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

DBV Technologies S.A. (DBVT) is the issuer in an amended beneficial-ownership disclosure in which MPM BioImpact LLC reported beneficial ownership of 15,223,295 ordinary shares, or 4.8% of the class, as of September 30, 2026. The reported ordinary shares are represented by ADSs; each ADS represents five ordinary shares.

Key Figures

Beneficially owned ordinary shares: 15,223,295 shares Percent of class: 4.8% ADS ratio: 5 ordinary shares per ADS

3 metrics

Beneficially owned ordinary shares 15,223,295 shares MPM BioImpact LLC; as of September 30, 2026

Percent of class 4.8% MPM BioImpact LLC’s reported beneficial ownership

ADS ratio 5 ordinary shares per ADS Each American Depositary Share represents five ordinary shares

Key Terms

Beneficially Owned, American Depositary Shares, Sole Voting Power, Sole Dispositive Power

4 terms

Beneficially Owned regulatory

"Amount beneficially owned: 15,223,295 Ordinary Shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

American Depositary Shares financial

"American Depositary Shares ("ADSs") of the Issuer"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Sole Voting Power regulatory

"Sole voting power: 15,223,295"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole dispositive power: 15,223,295"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DBVT ordinary shares did MPM BioImpact LLC report owning?

MPM BioImpact LLC reported beneficial ownership of 15,223,295 DBV Technologies ordinary shares, equal to 4.8% of the class, as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

DBV TECHNOLOGIES S.A.

(Name of Issuer)

Ordinary Shares, nominal value 0.10 euro per share

(Title of Class of Securities)

23306J309

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23306J309

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,223,295.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,223,295.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,223,295.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DBV TECHNOLOGIES S.A.
(b)	Address of issuer's principal executive offices: 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, I0, 92120.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Ordinary Shares, nominal value 0.10 euro per share
(e)	CUSIP No.: 23306J309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 23306J309 has been assigned to the American Depositary Shares ("ADSs") of the Issuer. Each ADS represents five Ordinary Shares. The shares reported herein for the Reporting Person include 15,223,295 Ordinary Shares represented by ADSs.
(b)	Percent of class: 4.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 15,223,295
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 15,223,295
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	11/13/2026